WESTLAKE VILLAGE, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in ...

Sudo Biosciences has begun a Phase I trial of SUDO-550, a drug candidate designed to treat neuroinflammatory diseases.

Summer heat can be an instigator for eczema and psoriasis flare-ups – two common skin conditions that cause discomfort, ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

We think UCB is in good financial health, with solid earnings and cash flow generation. UCB has deleveraged over the years, and it ended 2023 with about EUR 2.2 billion in net debt on its balance ...

Discover how nail health is a crucial indicator of overall wellness. Learn about what your nails reveal about nutritional ...

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

A recent research letter reveals a strong connection between the consumption of ultra-processed foods and psoriasis flare-ups ...

Deucravacitinib outperformed placebo for treating moderate to severe scalp psoriasis, even among patients with less extensive overall disease.

A new study shows that the US is still behind in controlling the price of prescription drugs. One doctor explains why America ...